- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05619822
A Comprehensive Third-generation Intervention for People With Psychosis and Post-traumatic Stress Symptoms (IITG-PPT)
A Comprehensive Third-generation Intervention for People With Psychosis and Post-traumatic Stress Symptoms; Design, Implementation and Effectiveness
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a randomized clinical trial at psychiatric rehabilitation services of the Public Network of Care for people with serious mental disorders. We hypothesize that participants receiving the intervention, in comparison with controls, will show a reduction in general, PTSD and psychotic symptomatology, an improvement in levels of functioning and well-being, a greater ability to regulate emotions with more help-seeking behaviours.
Given the complexity of both psychosis and PTSD and the reluctance of professionals to treat it, we plan to develop a precise comprehensive protocol. In order to address all issues associated with both psychosis and comorbid PTSD, the protocol will be developed following the three stages of recovery from trauma: first, focusing on establishing the therapeutic alliance and safety; second, focusing on recounting and re-processing the traumatic event; and third, focusing on reconnecting with others and with life despite the trauma experienced. The therapy will be adapted to the characteristics of people with SMD and administered in 11 90-minute individual sessions per week, combining strategically ACT, Mindfulness, EMDR as well as Positive Psychology interventions.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spain, 28223
- Carmen Valiente
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Those showing a high risk of PTSD (TSQ ≥6) will be further evaluated to determine whether they meet the inclusion criteria. Participants must:
- Be between the ages of 18 and 65 fluent enough in Spanish language;
- Meet the criteria for a diagnosis of a psychotic spectrum disorder or a mood disorder with psychotic symptoms according to MINI (Sheeman et al., 1997);
- Meet PTSD diagnostic criteria according to the Clinician-Administered PTSD Scale (CAPS; Blake et al., 1995)
Exclusion Criteria:
- Those who have a diagnosis of substance or alcohol abuse or dependence in the 30 days prior to participation in the study
- To have a severe neurocognitive problems or brain damage that interfere with the basic processing of information in psychotherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: TAU + waiting list
Treatment as usual
|
Treatment as usual
|
Experimental: TAU + A comprehensive third-generation intervention
he protocol will bedeveloped following the three stages of recovery from trauma (Herman, 2015): first, focusing on establishing the therapeutic alliance and safety; second, focusing on recounting and re-processing the traumatic event; and third, focusing on reconnecting with others and with life despite the trauma experienced.
The therapy will be administered in 11 90-minute individual sessions per week, combining strategically ACT, Mindfulness, EMDR as well as Positive Psychology interventions.
|
This is a individual intervention with with a total of 12 sessions: Session 1. Constructing the Therapy Experience.
Session 2. Life history and immediate reactions to trauma.
Session 3. Preparing to deal with trauma.
Session 4. Regulating emotions.
Session 5-9.
Focusing on retelling and processing the traumatic event (EMDR PHASES_PHASE 3: Evaluation of the traumatic memory.
EMDR PHASE 4: Desensitization.
EMDR PHASE 5: Positive Belief Installation.
PHASE 6: Body Scan).
Session 9. Re-evaluating traumatic memory and self-care through positive emotions.
Session 10.
Cultivating self-kindness.
Session 11.
Developing a healthy identity.
Session 12. Building a better future
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from posttraumatic symptoms at 12 weeks and 6 months
Time Frame: Change baseline, 12 weeks, and 6 months
|
International Trauma Questionnaire (ITQ; Cloitre, et al., 2018).Higher scores mean a worse outcome.
|
Change baseline, 12 weeks, and 6 months
|
Change from psychotic symptoms at 12 weeks and 6 months
Time Frame: Change baseline, 12 weeks, and 6 months
|
Psychotic Symtoms Rating Scale (Haddock et al., 1999).Higher scores mean a worse outcome.
|
Change baseline, 12 weeks, and 6 months
|
Change from psychopathological symptoms at 12 weeks and 6 months
Time Frame: Change baseline, 12 weeks, and 6 months
|
Symptom Checklist 45-SCL-90_r brief (Davison et al., 1997).
Higher scores mean a worse outcome.
|
Change baseline, 12 weeks, and 6 months
|
Change from dissociative symptoms at 12 weeks and 6 months
Time Frame: Change baseline, 12 weeks, and 6 months
|
The Dissociative Experience Scale Taxon (DES-T; Waller & Ross, 1997).
Higher scores mean a worse outcome.
|
Change baseline, 12 weeks, and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Personal and Social functioning at 12 weeks and 6 months
Time Frame: Change baseline, 12 weeks, and 6 months
|
Personal and Social Performance Scale (PSP; Morosini y cols., 2000).
Higher scores mean a worse outcome.
|
Change baseline, 12 weeks, and 6 months
|
Change from Wellbeing at 12 weeks and 6 months
Time Frame: Change baseline, 12 weeks, and 6 months
|
Scales of Psychological Well-Being (SPWB; Ryff & Keyes,1995).
Higher scores mean a better outcome.
|
Change baseline, 12 weeks, and 6 months
|
Change from satisfaction with life at 12 weeks and 6 months
Time Frame: Change baseline, 12 weeks, and 6 months
|
Satisfaction with Life Scale (SWLS; Diener et al., 1985).
Higher scores mean a better outcome.
|
Change baseline, 12 weeks, and 6 months
|
Change from Attachment at 12 weeks and 6 months
Time Frame: Change baseline, 12 weeks, and 6 months
|
Psychosis Attachment Measure (PAM; Berry et al., 2006; Sheinbaum et al., 2013).
Higher scores mean a worse outcome.
|
Change baseline, 12 weeks, and 6 months
|
Change from Emotion Regulation at 12 weeks and 6 months
Time Frame: Change baseline, 12 weeks, and 6 months
|
Cognitive Emotion Regulation Questionnaire (CERQ; Garnefski & Kraaij, 2007).
Higher scores mean a worse outcome for disfunctional dimensions and a better outcome for functional dimensions
|
Change baseline, 12 weeks, and 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Carmen Valiente, Ph.D., Universidad Complutense de Madrid
- Principal Investigator: Regina Espinosa, Ph.D., Universidad Camilo Jose Cela
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCHIZO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychosis
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)Enrolling by invitationFirst Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)United States
-
University of UdineNational Research Council (CNR), Institute of Biomolecular Chemistry (ICB)...RecruitingClinical High Risk for Psychosis | Ultra High Risk for Psychosis | Attenuated Psychotic SymptomsItaly
-
University of New MexicoNational Institute of Mental Health (NIMH)CompletedPsychosis | Clinical High Risk for Psychosis | First Episode PsychosisUnited States
-
Shanghai Jiao Tong University School of MedicineGuangzhou Psychiatric Hospital; Suzhou Psychiatric Hospital; Tianjin Anding Hospital and other collaboratorsRecruitingSchizophrenia; Psychosis | Clinical High Risk | First Episode PsychosisChina
-
Chulalongkorn UniversityNational Research Council of Thailand; Thanyarak InstituteCompletedMethamphetamine-induced PsychosisThailand
-
University of California, San DiegoCenter for Medicinal Cannabis ResearchRecruitingEarly PsychosisUnited States
-
Yale UniversityCompleted
-
University of TorontoUniversity of British Columbia; Centre for Addiction and Mental Health; Queen... and other collaboratorsNot yet recruitingPsychotic Disorders | Schizophrenia | Psychosis | Schizophrenia; Psychosis
-
Northwell HealthNational Institute of Mental Health (NIMH)RecruitingFirst Episode PsychosisUnited States
-
State reference center for psychosocial careUniversity of ValenciaCompleted
Clinical Trials on TAU
-
Fundació Sant Joan de DéuUniversitat Autonoma de BarcelonaRecruiting
-
University of WashingtonUnited States Department of Defense; Military Suicide Research ConsortiumCompletedSuicidal and Self-injurious Behavior | Suicidal Ideation ActiveUnited States
-
Centro Mente Aberta de MindfulnessConselho Nacional de Desenvolvimento Científico e TecnológicoCompleted
-
IRCCS Centro Neurolesi "Bonino-Pulejo"Recruiting
-
Hospital Universitari Vall d'Hebron Research InstituteUniversitat Autonoma de Barcelona; Ministerio de Ciencia e Innovación, SpainNot yet recruiting
-
Virginia Commonwealth UniversityCompletedSubstance Use Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Drug Dependence | Drug Use Disorders | Substance AddictionUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteParc Sanitari Sant Joan de Déu; Universitat Autonoma de BarcelonaCompleted
-
University of Wisconsin, MadisonMedical University of South Carolina; National Heart, Lung, and Blood Institute...Completed
-
Norwegian Center for Violence and Traumatic Stress...Norway: Directorate for Health and Social AffairsCompletedPost-Traumatic Stress DisorderNorway
-
University of BernCompletedUnipolar Depression | Adjustment Disorder | Anxiety DisorderSwitzerland